These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11904966)

  • 21. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA; Foon KA
    Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monoclonal antibody therapy for malignant lymphoma].
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Med Klin (Munich); 2005 Jan; 100(1):14-24. PubMed ID: 15654538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-targeted immunotherapy for treatment of malignancy.
    White CA; Weaver RL; Grillo-López AJ
    Annu Rev Med; 2001; 52():125-45. PubMed ID: 11160771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-based therapy of non-Hodgkin's lymphoma.
    Foran JM
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Innovative antibody-therapies for malignant lymphomas].
    Müller AM; Rawluk J; Thierry V; Brink I; Engelhardt M
    Dtsch Med Wochenschr; 2005 Dec; 130(48):2783-8. PubMed ID: 16307409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
    Tobinai K
    Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston PB; Bondly C; Micallef IN
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic monoclonal antibodies in onco-hematology].
    Cartron G; Rossi JF
    Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.
    Wong ET
    Expert Opin Pharmacother; 2005 Jun; 6(7):1107-14. PubMed ID: 15957965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
    Feuring-Buske M; Buske C; Unterhalt M; Hiddemann W
    Ann Hematol; 2000 Apr; 79(4):167-74. PubMed ID: 10834503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
    Leonard JP
    Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical status and optimal use of rituximab for B-cell lymphomas.
    McLaughlin P; White CA; Grillo-López AJ; Maloney DG
    Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody therapy for B cell non-Hodgkin's lymphomas: emerging concepts of a tumour-targeted strategy.
    Buske C; Feuring-Buske M; Unterhalt M; Hiddemann W
    Eur J Cancer; 1999 Apr; 35(4):549-57. PubMed ID: 10492626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.